Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/4140
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNaushin, S-
dc.contributor.authorSardana, V-
dc.contributor.authorUjjainiya, R-
dc.contributor.authorBhatheja, N-
dc.contributor.authorSukumaran, R-
dc.contributor.authorNair, A R-
dc.contributor.authorValappil, P K-
dc.contributor.authorPuthiyamadam, A-
dc.contributor.authorVelayudhanpillai, A-
dc.date.accessioned2022-11-28T16:12:16Z-
dc.date.available2022-11-28T16:12:16Z-
dc.date.issued2021-04-20-
dc.identifier.citationeLife;10: e66537en_US
dc.identifier.urihttps://doi.org/10.7554/elife.66537-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/4140-
dc.description.abstractTo understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92–2.59, <0.0001), use of public transport (1.79, 1.43–2.24, <0.0001), not smoking (1.52, 1.16–1.99, 0.0257), non-vegetarian diet (1.67, 1.41–1.99, <0.0001), and B blood group (1.36, 1.15–1.61, 0.001).en_US
dc.language.isoenen_US
dc.publishereLife Sciencesen_US
dc.subjectSero-Epidemiologicalen_US
dc.subjectSARS-CoV2en_US
dc.titleInsights From a Pan India Sero-Epidemiological Survey (Phenome-India Cohort) for SARS-CoV2en_US
dc.typeArticleen_US
Appears in Collections:2021

Files in This Item:
File Description SizeFormat 
Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2_Naushin_eLIFE.pdf
  Restricted Access
2.12 MBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.